 October 31, 2007
|
HIV Treatment Greatly Improves Brain Illness Survival
Combination antiretroviral (ARV) treatment has significantly increased survival in people diagnosed with AIDS-related illnesses of the brain, according to data presented at the 11th European AIDS Conference in Madrid.
|
|
|
October 30, 2007
|
Is Once-Daily Kaletra an Effective Dosing Option?
An international study comparing Norvir (ritonavir)-boosted Prezista (darunavir) to Kaletra (lopinavir/ritonavir) in people starting treatment for the first time has reported a surprising secondary finding—better virologic control among patients with high pre-therapy viral loads using twice daily, as opposed to once daily, Kaletra.
|
|
|
October 29, 2007
|
Small Steps Forward in HIV Prevention
Slow but steady progress is being made on several HIV prevention fronts, say researchers in a special symposium on HIV prevention at the 11th European AIDS Conference.
|
|
|
October 27, 2007
|
Crestor Bests Pravachol for Elevated Lipids
Crestor is superior to Pravachol in HIV-positive people on antiretroviral therapy who experience LDL cholesterol and triglyceride elevations, according to new data presented at the 11th EACS in Madrid.
|
|
|
New Menu of Antiviral Options
 Dr. José Gatell talks with David Evans about the latest treatment news on Selzentry, rilpivirine (TMC278) and the continued interest in Kaletra monotherapy.
|
|
|
Children and Challenges: Treating Pediatric HIV
 Over 2 million children are living with HIV/AIDS throughout the world. Dr. José Ramos talks with Peter Staley about the unique challenges facing HIV-positive children and their health care providers.
|
|
|
October 26, 2007
|
Rilpivirine Comparable to Sustiva in Treatment First-Timers
The experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine is comparable to Sustiva in terms of reducing HIV levels and increasing CD4 counts over 48 weeks in people taking antiretroviral treatment for the first time.
|
|
|
Tesamorelin (TH9507) Safe and Effective for 52 Weeks
HIV-positive patients with lipodystrophy can be treated safely and effectively with tesamorelin (TH9507) for at least 52 weeks, according to new data presented this week at the 11th European AIDS Conference in Madrid.
|
|
|
October 25, 2007
|
Strategies for Success With Kaletra Monotherapy
Two reports regarding the experimental use of Kaletra (lopinavir/ritonavir), without other medications, show that it can successfully keep HIV under control, and offer predictions regarding who will most likely benefit from the use of Kaletra monotherapy.
|
|
|
| October 24, 2007
|
October 23, 2007
|
Kaletra Reduces HIV in the Brain
Kaletra (lopinavir/ritonavir) significantly reduces HIV levels in the brain, say researchers of a new study published in Clinical Infectious Diseases.
|
|
|
October 19, 2007
|
ESRD Nearly Six Times Higher in African Americans With HIV
The risk of developing end-stage renal disease (ESRD) is significantly higher in African Americans with HIV than in whites who are HIV positive, according to a press release summarizing a study published in the November Journal of the American Society of Nephrology.
|
|
|
October 18, 2007
|
HIV Increases Risk of Heparin-Induced Thrombocytopenia
HIV-positive people using heparin for blood clots are more likely than HIV-negative people using the drug to experience a potentially dangerous drop in their platelet counts, according to a report in the November 15 issue of Clinical Infectious Diseases.
|
|
|
| October 17, 2007
|
October 16, 2007
|
Rapid Liver Damage Possible in HIV/HCV Patients
Nearly one quarter of people who are coinfected with HIV and hepatitis C virus (HCV) may experience rapid liver damage, say researchers of a study published in the October 2007 issue of AIDS.
|
|
|
| October 12, 2007
|
October 10, 2007
|
Stress May Contribute to HIV Disease Progression
People with HIV who have high levels of stress may progress to AIDS more rapidly, according to a press release summarizing study results reported in the most recent issue of the Journal of the American Medical Association (JAMA).
|
|
|
People on a Failing HIV Regimen May Still See Benefit
HIV-positive people with few or no remaining antiretroviral options may still benefit from staying on a drug regimen that is no longer controlling the virus, according to new data published in the October 15 issue of Clinical Infectious Diseases.
|
|
|
| October 09, 2007
|
| October 08, 2007
|
October 04, 2007
|
Needle-Free Fuzeon Abandoned for Now
Roche and Trimeris, Inc. have announced that they will no longer pursue government approval to market a needle-free injection device for use with their entry inhibitor, Fuzeon (enfuvirtide).
|
|
|
October 03, 2007
|
Key Protein Blunts Immune System’s Power to Fight HIV
Researchers at the Partners AIDS Research Center at Massachusetts General Hospital announce that they have uncovered a mechanism that suppresses the immune system’s ability to control HIV, possibly resulting in a new target for HIV treatment.
|
|
|
October 02, 2007
|
Scientists Discover a Way to Reach Hidden HIV
Researchers at Philadelphia’s Jefferson Medical College have found that blocking small pieces of genetic material called microRNA (miRNA) could help antiretroviral drugs reach HIV that hides out in CD4 cells.
|
|
|
October 01, 2007
|
Acetyl-L-Carnitine Promising for Neuropathy
In a recent article in the journal CNS Drugs, Michael Youle, MD, a noted HIV specialist at London’s Royal Free Hospital, claims that acetyl-L-carnitine (LAC), an over-the-counter amino acid supplement, is a promising treatment for a condition known as peripheral neuropathy.
|
|
|
|
Want to have a baby? Dr. Valerie Stone checks in with David Evans about family planning for couples living with HIV. 
HIV and its medications may increase the risk of cardiovascular disease, but Dr. Jens Lundgren tells Peter Staley that there's a lot to be said for preventive strategies. 
Dr. Jonathan Schapiro tells Peter Staley that an undetectable viral load is almost always an obtainable goal, even for highly treatment-experienced patients with drug-resistant HIV. 
